These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34885078)

  • 41. TCR Bispecific Boosts Survival in Uveal Melanoma.
    Cancer Discov; 2021 Jun; 11(6):1312. PubMed ID: 33839690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients.
    Tomsitz D; Kerl K; French LE; Heinzerling L
    J Am Acad Dermatol; 2024 Aug; ():. PubMed ID: 39216820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ensuring equity in the era of HLA-restricted cancer therapeutics.
    Smithy JW; Blouin A; Diamond LC; Postow M
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442912
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
    Jindal V
    Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
    Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action.
    Hassel JC; Stanhope S; Greenshields-Watson A; Machiraju D; Enk A; Holland C; Abdullah SE; Benlahrech A; Orloff M; Nathan P; Piperno-Neumann S; Staeger R; Dummer R; Meier-Schiesser B
    J Invest Dermatol; 2024 Jul; ():. PubMed ID: 39019150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted therapy for uveal melanoma.
    Triozzi PL; Eng C; Singh AD
    Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
    Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
    Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Trials in Metastatic Uveal Melanoma: Current Status.
    Sussman TA; Funchain P; Singh A
    Ocul Oncol Pathol; 2020 Dec; 6(6):381-387. PubMed ID: 33447587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Uveal Melanoma.
    Shoushtari AN; Carvajal RD
    Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uveal melanoma.
    Spagnolo F; Caltabiano G; Queirolo P
    Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
    López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1219-27. PubMed ID: 17325166
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
    Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
    Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.
    Natali PG; Bigotti A; Nicotra MR; Nardi RM; Delovu A; Segatto O; Ferrone S
    Cancer Res; 1989 Mar; 49(5):1269-74. PubMed ID: 2917356
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.